Short-Term Success, Long-Term Failure: Strain Turnover and Virulence Re-Emergence May Drive Relapse in Pouchitis: GI Signals

IBD prospective cohort · n=21 · Sep 9, 2026 · Gastroenterology · IF 25.1

Short-Term Success, Long-Term Failure: Strain Turnover and Virulence Re-Emergence May Drive Relapse in Pouchitis.

Basic sciencepouchitismicrobiomeIBD surgery

Clinical takeawayNo clinical action yet: this is mechanistic evidence in human samples explaining why antibiotic-induced remission is transient in pouchitis. It does not test a new treatment or monitoring strategy. The finding supports the hypothesis that subsequent flares are driven by microbial re-expansion rather than new infection, positioning the need for approaches that sustain microbial control beyond antibiotics. Such approaches (e.g., targeted antimicrobials, FMT, or probiotics) are not yet evaluated here.

What it foundAntibiotic treatment suppresses exotoxin-producing bacteria (fecal calprotectin 728 to 265 μg/g) but allows pre-existing antibiotic-resistant, low-virulence strains to expand; resistant strains and exotoxin genes rebound by 6 weeks post-treatment, explaining relapse.

ContextCurrent first-line pouchitis treatment is antibiotics (metronidazole with or without a quinolone or tetracycline). This study confirms rapid clinical improvement but shows mechanistically why antibiotic-induced remission is transient: antibiotics create a permissive niche for resistant strains, which persist after treatment stops. This refines understanding of why relapses occur after antibiotic monotherapy but does not challenge the current initial treatment recommendation.

Emergingsuggested applicable standard· ACG Clinical Guideline Update: Ulcerative Colitis in Adults, Am J Gastroenterol 2025;120(6):1187-1224; AGA Living Guideline on Pharmacological Management of Moderate-to-Severe UC, Gastroenterology 2024 (panel review March 2026, no changes)

Decision at stakemanagement of pouchitis occurring after IPAA reconstruction in ulcerative colitis patients

Confirm ulcerative colitis with endoscopy showing continuous colonic inflammation from the rectum plus histology, after excluding infection with two-step CDI testing. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Confirm ulcerative colitis with endoscopy showing continuous colonic inflammation from the rectum plus histology, after excluding infection with two-step CDI testing. Treat mild-moderate disease with 5-ASA by route and extent (suppository for proctitis, enema for left-sided, oral plus rectal for extensive); if 5-ASA fails, treat as moderate-to-severe rather than stepping up gradually. Position advanced therapy by EFFICACY TIER, not by an anti-TNF-first rule. Advanced-therapy-naive, higher efficacy: infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib, risankizumab, guselkumab; intermediate: golimumab, ustekinumab, tofacitinib, filgotinib, mirikizumab; lower: adalimumab. PREVIOUSLY TNF-EXPOSED, higher efficacy: tofacitinib, upadacitinib, ustekinumab; lower: adalimumab, vedolizumab, ozanimod, etrasimod - S1P modulators are weakest in exactly this group. Do not cycle within the anti-TNF class after primary non-response; switch mechanism. Apply treat-to-target (STRIDE-II) to endoscopic improvement (MES 0-1). Screen for acute severe UC by Truelove-Witts and admit for IV steroids. Begin CRC surveillance 8-10 years after DIAGNOSIS for extensive or left-sided disease; isolated proctitis follows average-risk screening.

ACG Clinical Guideline Update: Ulcerative Colitis in Adults, Am J Gastroenterol 2025;120(6):1187-1224; AGA Living Guideline on Pharmacological Management of Moderate-to-Severe UC, Gastroenterology 2024 (panel review March 2026, no changes) ↗

Bilinsky L … Dotan I · Gastroenterology · IF 25.1 · PubMed ↗Permalink